^
    Back
    Association details:
    Biomarker:Chr del(17p)
    Cancer:Chronic Lymphocytic Leukemia
    Drug:Zydelig (idelalisib) (PI3Kδ inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Suggested treatment regimens...CLL/SLL with del(17p)/TP53 mutation…Relapsed/refractory therapy…preferred regimen…idelalisib
    Evidence Level:
    Sensitive: B - Late Trials
    New
    Source:
    Ann Oncol
    Title:

    Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients

    Excerpt:
    Patients who received ibrutinib-based therapy (versus idelalisib-based therapy) as their first KI experienced a significantly better PFS in all settings; front-line (HR 2.8, CI 1.3–6.3, P = 0.01), relapsed-refractory (HR 2.8, CI 1.9–4.1, P < 0.001), del17p (HR 2.0, CI 1.2–3.4, P = 0.008), or complex karyotype (HR 2.5, CI 1.2–5.2, P = 0.02).
    DOI:
    10.1093/annonc/mdx031
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Go to data
    Source:
    clinicaltrials.gov
    Title:

    Efficacy and Safety of Idelalisib in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia

    Excerpt:
    ...Overall Response Rate`Lymph Node Response Rate`Overall Survival`Progression-Free Survival in Subgroup of Participants With Chromosome 17p Deletion and/or TP53 Mutation`Complete Response Rate...
    Trial ID:
    NCT01659021
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    J Clin Oncol
    Title:

    Updated results of a phase III randomized, controlled study of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukemia (CLL).

    Published date:
    05/20/2016
    Excerpt:
    Pts with CLL progressing ≤ 24 mo from last therapy...With > 8 mos longer follow-up, IDELA + OFA vs OFA continues to show superior PFS and ORR, and now demonstrates superior OS in pts with del17p/TP53mut and a trend of improvement of OS in the ITT population.
    DOI:
    10.1200/JCO.2016.34.15_suppl.7515
    Trial ID:
    NCT01659021